Market revenue in 2023 | USD 198.1 million |
Market revenue in 2030 | USD 1,092.9 million |
Growth rate | 27.6% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Therapeutics |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Therapeutics, Diagnostics |
Key market players worldwide | Novartis AG ADR, Oncopeptides AB, Bicycle Therapeutics PLC ADR, AstraZeneca PLC, Theratechnologies Inc, Cybrexa Therapeutics, AngioChem, Soricimed |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide drug conjugates market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.47% in 2023. Horizon Databook has segmented the Europe peptide drug conjugates market based on therapeutics, diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
Europe held the second-largest share in the global market in 2022, following North America, and is estimated to grow at a lucrative CAGR over the forecast period. The market growth can be attributed to an increase in research funding and the presence of key market players in this region.
The number of biopharmaceutical companies is growing in Europe owing to increasing investments. Moreover, the population in Europe is rapidly aging. This population is at a relatively high risk of developing various target diseases, including cancer, cardiovascular diseases, and neurological disorders, as the risk of developing these conditions & hospitalization rates are relatively higher in older patients.
Furthermore, the market is experiencing a notable surge in demand due to various factors, including the increasing need for peptide-based treatments across a range of diseases, the swift integration of peptide therapies for addressing cancer, continuous progress in formulating novel therapies & medications in peptides, and an emphasis on creating nanoparticle-based peptide drugs for diabetes management.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe peptide drug conjugates market , including forecasts for subscribers. This continent databook contains high-level insights into Europe peptide drug conjugates market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account